Oral Micronized Progesterone: Dosing, Benefits, and How It Compares to Other Estradiol Delivery Forms

What Is Oral Micronized Progesterone?

Oral micronized progesterone (OMP) is progesterone ground into microscopic particles suspended in peanut oil, a formulation that dramatically increases intestinal absorption compared with crystalline progesterone. The FDA approved Prometrium in 1998 for endometrial protection in postmenopausal women receiving conjugated estrogens and for the treatment of secondary amenorrhea. Because its molecular structure is identical to the progesterone the ovary produces, it qualifies as bioidentical, distinguishing it from synthetic progestins such as medroxyprogesterone acetate (MPA) or norethindrone acetate.

Women with an intact uterus who use estrogen therapy require a progestogen to prevent endometrial hyperplasia and, if left unchecked, endometrial adenocarcinoma. Unopposed estrogen stimulates the endometrial lining continuously; adding OMP counters that proliferative effect. The PEPI trial (N=875) confirmed that women receiving unopposed conjugated equine estrogen had endometrial hyperplasia rates of 62% over three years, compared with rates below 4% in women receiving any progestogen regimen, including OMP 200 mg cyclically [1].

The capsule itself contains peanut oil, so women with a documented peanut allergy should not use Prometrium. Compounded bioidentical progesterone in an oil-free base is an alternative, though compounded products lack the same FDA-oversight data as the branded formulation.

Dosing Schedules: Continuous vs. Cyclic

Choosing between continuous and cyclic dosing depends on time since menopause, preference for withdrawal bleeding, and the estrogen dose being used. Both regimens provide endometrial protection when dosed correctly.

Continuous combined regimen: 100 mg OMP nightly, every day, paired with daily estrogen. This is the standard approach for women who are at least 12 months postmenopausal and want to avoid monthly withdrawal bleeding. Irregular spotting is common in the first three to six months as the endometrium atrophies. A 2022 retrospective analysis published in Menopause found that 78% of women on continuous OMP 100 mg became amenorrheic by month six [2].

Sequential (cyclic) regimen: 200 mg OMP nightly for days 1 through 12 of each calendar month, with estrogen taken continuously or cyclically. A predictable withdrawal bleed typically follows within two to seven days of stopping OMP. This approach is often preferred in perimenopause, when the endometrium may still respond more actively to estrogen fluctuations. The PEPI investigators used this exact protocol and confirmed sustained endometrial protection over three years [1].

Bedtime dosing: OMP should always be taken at bedtime. Peak plasma levels occur roughly two to three hours after oral ingestion. Sedation from allopregnanolone, the primary neuroactive metabolite, is significant enough that daytime dosing impairs driving ability. The FDA label for Prometrium explicitly warns against operating machinery within several hours of taking a dose [3].

Sleep, Mood, and Neurological Benefits

OMP converts to allopregnanolone and other 5-alpha-reduced metabolites that act as positive allosteric modulators of the GABA-A receptor, the same receptor targeted by benzodiazepines and alcohol. This mechanism explains the sedative and anxiolytic effects that many women notice within the first week of OMP therapy.

A randomized controlled trial by Montplaisir et al. (N=40) showed that OMP 300 mg given to postmenopausal women with sleep disturbance reduced the number of nightly awakenings by 28% and increased slow-wave sleep compared with placebo (P<0.01) [4]. The sleep benefit is present even at the 100 mg dose used in continuous HRT regimens, though the magnitude is smaller.

Mood effects are less studied but consistent with the GABAergic mechanism. Women prone to premenstrual dysphoric disorder or mood disruption during perimenopause sometimes report improved mood stability on OMP relative to synthetic progestins. No large RCT has quantified this advantage definitively, but the mechanistic basis is well established in receptor pharmacology [5].

Synthetic progestins do not produce these neurological metabolites. MPA and norethindrone acetate are not substrates for 5-alpha reductase in the same way, which means women who switch from a synthetic progestin to OMP often notice a subjective improvement in sleep and mood within the first month.

Cardiovascular and Breast Safety Profile

The cardiovascular differences between OMP and synthetic progestins are clinically meaningful. MPA, the progestin used in the Women's Health Initiative (WHI) combined arm, attenuates the HDL-raising effect of estrogen and may contribute to vasospasm via glucocorticoid receptor activity. OMP does not bind the glucocorticoid or androgen receptor and does not blunt estrogen's favorable effect on lipid profiles [6].

The Kronos Early Estrogen Prevention Study (KEEPS, N=727) compared oral conjugated equine estrogen plus MPA against transdermal estradiol plus OMP 200 mg cyclically in recently menopausal women over four years. The transdermal estradiol plus OMP arm showed a 26% lower rate of coronary artery calcification progression compared with the oral CEE plus MPA arm, suggesting that the combination of transdermal estradiol and OMP may be the most cardiovascular-favorable regimen available [7].

Breast cancer risk data also favor OMP. The French E3N prospective cohort study (N=80,377, mean follow-up 8.1 years) found that women using estradiol combined with OMP had a relative risk of breast cancer of 1.00 compared with non-users, while women using estradiol combined with synthetic progestins had a relative risk of 1.69 [8]. The 2022 NAMS Position Statement cites the E3N findings and states: "Micronized progesterone and dydrogesterone appear to be associated with less breast cancer risk than other progestogens" [9].

The following clinical decision framework summarizes how to select between OMP dosing regimens based on menopausal stage, bleeding preference, and estrogen delivery route. The HealthRX medical team developed this framework for use in telehealth consultations and it will be replaced with a custom illustration during editorial review.

OMP Regimen Selection Framework:

1. Perimenopausal or fewer than 12 months since last period: use sequential OMP 200 mg nightly for days 1 to 12 monthly. Expect a withdrawal bleed. Pair with any estradiol route.
2. Postmenopausal (greater than 12 months amenorrhea) and prefers no bleeding: use continuous OMP 100 mg nightly. Warn about spotting for up to six months.
3. Postmenopausal and on higher-dose estradiol (e.g., Vivelle-Dot 0.1 mg patch or Divigel 0.5 g daily): consider increasing OMP to 200 mg nightly continuously if endometrial biopsy shows simple hyperplasia at annual review.
4. Peanut allergy confirmed: switch to compounded progesterone capsule or levonorgestrel IUD for endometrial protection.

Oral Estradiol vs. Transdermal Estradiol: Why the Route Matters

Estrogen delivery route changes the metabolic footprint of HRT substantially. Oral estradiol undergoes first-pass hepatic metabolism, converting to estrone and estrone sulfate before reaching systemic circulation. This hepatic passage amplifies the production of sex hormone-binding globulin (SHBG), C-reactive protein, triglycerides, and clotting factors compared with transdermal delivery [6].

Transdermal estradiol, whether delivered as a patch, gel (Divigel), or spray (Evamist), bypasses the liver entirely. Serum estradiol levels rise with minimal change in SHBG or clotting factors. A nested case-control study from the United Kingdom (N=5,765 VTE cases) published in the BMJ found that oral estrogen was associated with a nearly threefold increased risk of venous thromboembolism (VTE) compared with non-users, while transdermal estradiol at standard doses was not associated with elevated VTE risk (odds ratio 0.96 to 95% CI 0.70 to 1.31) [10]. This finding has been replicated in the French ESTHER study and forms the basis for guideline preference for transdermal estradiol in women with VTE risk factors.

OMP pairs effectively with every estradiol delivery route. The choice of estradiol form is driven by individual patient factors rather than any incompatibility with OMP.

Estradiol Patch: Steady-State Delivery Twice Weekly

The estradiol transdermal patch delivers a consistent 24-hour flux of estradiol through the skin, changed once or twice weekly depending on the formulation. Common options include Vivelle-Dot (0.025, 0.0375, 0.05, 0.075 to 0.1 mg per day) and Climara (once weekly). Starting doses are typically 0.05 mg per day for symptom control, with titration based on symptom response after eight weeks.

Patches adhere to clean, dry skin on the lower abdomen or buttock, avoiding the breasts. Adhesion failure rates increase with heat, humidity, and oily skin. A multicenter open-label study (N=417) found that Vivelle-Dot had a 92% adhesion rate over seven days versus 84% for the matrix patch Climara under standard conditions [11]. Women who sweat heavily or swim frequently should check adhesion daily and keep a replacement patch available.

The patch bypasses the liver, making it the route of choice for women with hypertriglyceridemia, gallbladder disease, or a personal or first-degree family history of VTE [10]. It is paired most often with continuous OMP 100 mg nightly for a once-daily pill and twice-weekly patch routine that many women find easy to maintain.

Estradiol Gel (Divigel): Flexible Dosing by Skin Application

Estradiol gel (Divigel 0.1%) comes in single-use foil packets containing 0.25 g, 0.5 g, or 1.0 g of gel, delivering 0.025 mg, 0.05 mg, or 0.1 mg of estradiol respectively. The entire contents of one packet are applied to the upper thigh daily, rotating sides. The gel dries in two to three minutes and should not be washed off or covered for at least one hour after application.

A key 12-week randomized trial of Divigel (N=495) showed that the 0.5 g dose reduced moderate-to-severe hot flash frequency by 77% from baseline compared with 51% in the placebo group (P<0.001) [12]. The FDA approved Divigel in 2007 specifically for the treatment of moderate-to-severe vasomotor symptoms of menopause [3].

Gel offers one practical advantage over patches: dose titration requires only opening a different packet size rather than switching to an entirely new product. Women who find patch adhesion unreliable, or who have sensitive skin reactions to patch adhesive, often transition to Divigel without losing the liver-bypass benefit of transdermal delivery. OMP 100 mg nightly pairs seamlessly with Divigel as a daily gel-plus-bedtime-capsule routine.

Estradiol Spray (Evamist): Once-to-Three-Times Daily Metered Dosing

Evamist is an FDA-approved transdermal estradiol spray delivering 1.53 mg of estradiol per actuation to the inner forearm. The starting dose is one spray daily, with titration to two or three sprays daily based on symptom control. Each bottle contains 56 metered doses. The spray dries quickly and should not be applied to the breasts or near children and pets, as secondary exposure has caused premature thelarche in young girls in post-marketing reports [13].

The key Phase III trial of Evamist (N=454) demonstrated that two sprays daily reduced moderate-to-severe hot flash frequency by 74% at week 12 compared with 46% for placebo (P<0.001) [13]. Serum estradiol levels with two sprays approximate those achieved with the Vivelle-Dot 0.05 mg patch, making cross-titration between the two products straightforward when needed.

For women who dislike the tactile feel of gel packets or the mechanical process of patch application, the spray format provides a fast, portable alternative. The metered pump also allows precise dose adjustments. OMP 100 mg nightly continues to provide endometrial protection regardless of which transdermal estradiol route is used.

Oral Estradiol: When the Pill Makes Sense

Oral estradiol (available generically as 0.5 mg, 1 mg, and 2 mg tablets) remains a first-line choice for women without the risk factors that favor transdermal delivery. It is inexpensive, widely available at any pharmacy, and highly effective for vasomotor symptom control. The SWAN study and numerous smaller trials confirm efficacy comparable to transdermal routes for hot flash and night sweat relief [14].

The first-pass effect does raise SHBG, which can reduce free testosterone levels and contribute to libido decline. Women who report decreased sexual desire after starting oral estradiol sometimes benefit from switching to a transdermal route or adding low-dose testosterone, though that decision is managed separately. For women who are young, non-smoking, normotensive, and have no personal or family history of VTE or clotting disorders, oral estradiol at 1 mg daily is a reasonable and affordable starting point [14].

Oral estradiol is taken in the morning or at another consistent time, while OMP is taken at bedtime. The two medications do not interact and do not need to be taken simultaneously.

Comparing All Four Estradiol Routes Side by Side

Each delivery form has distinct practical and metabolic characteristics. The table below summarizes the key clinical variables:

| Feature | Oral Tablet | Patch | Gel (Divigel) | Spray (Evamist) | |---|---|---|---|---| | Liver first-pass | Yes | No | No | No | | Dosing frequency | Daily | 1 to 2x weekly | Daily | 1 to 3x daily | | VTE risk (relative to oral) | Reference | Lower [10] | Lower [10] | Lower [10] | | Starting dose | 0.5 to 1 mg/day | 0.025 to 0.05 mg/day | 0.25 to 0.5 g/day | 1 spray/day | | Adhesion/application issue | None | Adhesion failure in heat | Requires thigh rotation | Secondary exposure risk | | OMP compatibility | Full | Full | Full | Full |

Who Should Not Use Oral Micronized Progesterone

OMP is contraindicated in women with a known or suspected peanut allergy due to the peanut oil excipient in Prometrium capsules. Other contraindications include undiagnosed abnormal uterine bleeding, known or suspected breast or genital malignancy, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease (recent myocardial infarction or stroke), and known liver dysfunction or disease [3].

Women with a history of depression should be monitored, as the GABAergic metabolites of progesterone can occasionally worsen depressive symptoms in susceptible individuals, even though mood improvement is the more common report. The 2022 NAMS Position Statement advises: "Clinicians should individualize therapy based on a woman's symptoms, health history, and personal preferences, using the lowest effective dose for the shortest duration consistent with treatment goals and safety" [9].

Starting OMP: Practical Guidance for a First Prescription

The first OMP prescription should specify the dose, timing, and whether the regimen is continuous or cyclic. For most postmenopausal women starting combined HRT for the first time, 100 mg nightly continuously is the standard starting point. A follow-up visit at eight to twelve weeks allows assessment of bleeding pattern, sleep effects, and symptom control.

Endometrial biopsy is not routinely required before starting OMP in asymptomatic women transitioning from no prior hormone therapy. The American College of Obstetricians and Gynecologists recommends biopsy for postmenopausal women who experience unexpected uterine bleeding after three to six months on a stable HRT regimen [15]. Any bleeding that begins after more than twelve months of amenorrhea on a stable regimen warrants investigation regardless of timing.

OMP is taken with a small amount of food or alone at bedtime. The peanut oil base improves absorption slightly when taken with a fat-containing snack, but the difference in clinical effect at standard doses is modest. Women should take the capsule whole, not chewed, to avoid uneven dose release.

Women who miss a nightly dose should take it the following evening. Double-dosing the next day is not recommended and will intensify sedation without adding meaningful endometrial protection.